Undifferentiated
endometrial carcinoma is an aggressive type of
uterine cancer, which is occasionally associated with a low-grade
endometrioid carcinoma component. This combination is referred to as "dedifferentiated endometrioid
endometrial carcinoma." Neuroendocrine expression may occur in undifferentiated
endometrial carcinoma, but its significance in dedifferentiated
endometrial carcinomas is unknown. To gain insight into the pathogenesis of these
tumors we have analyzed the immunophenotype (ARID1A, MLH1, PMS2, MSH2, MSH6, p53, β-
catenin, SMARCB1,
synaptophysin,
chromogranin A, and CD56) and mutational status (PTEN, KRAS, PIK3CA, TP53 and POLE) of 4 dedifferentiated
endometrial carcinomas with strong and diffuse neuroendocrine expression. All
tumors demonstrated neuroendocrine expression in ≥70% of the cells in the
undifferentiated carcinoma areas. Loss of expression of at least 1 DNA mismatch repair
protein was observed in 2 cases, and p53 immunoreaction was aberrant (mutated/inactivated) in one case. All
carcinomas were negative for β-
catenin and maintained nuclear SMARCB1 (INI1) and ARID1A expression. Three
tumors shared identical endometrioid molecular profile (PTEN and/or PIK3CA mutations) in both components. One
tumor had POLE
exonuclease domain mutation in the undifferentiated component. In one case, TP53 mutation was found exclusively in the undifferentiated component. Two patients died with
peritoneal carcinomatosis and abdominal
metastases, respectively; one patient died of a
renal failure without evidence of disease, and the last patient is alive and free of disease at 3.3 years. Dedifferentiated
endometrial carcinomas with neuroendocrine features are clinically and molecularly heterogeneous
tumors. Probably, these
carcinomas might acquire undifferentiated phenotype through mutations in TP53 and POLE.